Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr 6;60(4):1585-1587.
doi: 10.1093/rheumatology/keab061.

Baricitinib set to join the Covid-19 therapeutic arsenal?

Tania Gudu  1 , Carmel Stober  1 , Andrew P Cope  2 , Joseph Cheriyan  3   4 , James Galloway  2 , Ian B Wilkinson  3   4 , Michalis Kostapanos  4   5 , David Jayne  6 , Frances Hall  1
Affiliations
Editorial

Baricitinib set to join the Covid-19 therapeutic arsenal?

Tania Gudu et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Molecular targets of baricitinib Baricitinib inhibits several molecules, shown in the figure in red. These include Janus kinase proteins (JAK1 and JAK2) and closely related tyrosine kinase 2 (TYK2), which transduce signals through a range of type I and type II cytokine receptors. Baricitinib thereby has a broad suppressive effect across innate and adaptive immune pathways, including the acute phase response, antiviral response to interferons and lymphocyte proliferation and differentiation. Baricitinib also has a direct antiviral effect via inhibition of angiotensin-converting enzyme 2 (ACE2)-mediated enocytosis in clarthrin-coated pits.
See this image and copyright information in PMC

Comment in

References

    1. Zhou T, Su TT, Mudianto T, Wang J.. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med 2020;217:e20200674. - PMC - PubMed
    1. Jorgensen SCJ, Tse CLY, Burry L, Dresser LD.. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy 2020;40:843–56. - PMC - PubMed
    1. RECOVERY Collaborative Group; Horby P, Lim WS. et al.Dexamethasone in hospitalized patients with Covid-19 – Preliminary report. N Engl J Med (in press), doi: 10.1056/NEJMoa2021436. - PMC - PubMed
    1. Kalil AC, Patterson TF, Mehta AK. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med (in press), doi: 10.1056/NEJMoa2031994. - PMC - PubMed
    1. Stebbing J, Krishnan V, Bono S. et al.; Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 2020;12:e12697. - PMC - PubMed

Publication types

MeSH terms